Stock events for Alpha Teknova, Inc. (TKNO)
Alpha Teknova's stock price has experienced a significant decline over the past year and six months. The company reported its Fourth Quarter and Full Year 2025 financial results on February 26, 2026. For the full year 2025, total revenue increased by 7% to $40.5 million, with fourth-quarter revenue up 8% year-over-year to $10.0 million. Gross margin improved to 33.2% from 19.2% in 2024, and the net loss narrowed to $17.3 million (negative $0.32 per share) from $26.7 million. Adjusted EBITDA also improved to negative $6.7 million from negative $14.5 million. The company guided 2026 revenue to $42–44 million and aims for adjusted EBITDA positivity by the end of 2027. Despite these improvements, the stock has underperformed the US Life Sciences industry and the broader US market over the past year.
Demand Seasonality affecting Alpha Teknova, Inc.’s stock price
No specific information regarding demand seasonality for Alpha Teknova, Inc.'s products and services was found in the provided search results.
Overview of Alpha Teknova, Inc.’s business
Alpha Teknova, Inc. is a life science tools and reagents company that develops, manufactures, and distributes critical reagents. It operates within the Healthcare sector, specifically in the Healthcare Equipment & Supplies industry, and can also be categorized under Specialty Chemicals and Biotechnology. The company's primary products include pre-poured media plates, liquid cell culture media, and molecular biology reagents. They offer 'lab essentials' and 'clinical solutions,' serving a broad life sciences market including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions.
TKNO’s Geographic footprint
Headquartered in Hollister, California, Alpha Teknova, Inc. serves a global customer base. The company has sales and distribution channels across North America, Europe, and Asia, and derives key revenue from the United States.
TKNO Corporate Image Assessment
Alpha Teknova's brand reputation appears positive, with the company scoring higher than 68% of companies evaluated by MarketBeat and ranking 286th out of 870 stocks in the medical sector. Analyst sentiment is largely positive, with a consensus 'Hold' rating and an average target price suggesting a significant potential upside of approximately 279.1% from its current price. In 2025, the CEO highlighted strong overall execution, including accelerated top-line revenue growth, a 25% increase in clinical product customers, and approximately 95% of products delivered on time. No specific events negatively impacting Alpha Teknova's reputation in the past year were identified in the search results.
Ownership
Alpha Teknova, Inc. has 123 institutional owners and shareholders holding a total of 7,751,010 shares. Major institutional owners include Roubaix Capital, LLC, Balyasny Asset Management Llc, UBS Group AG, BlackRock, Inc., Vanguard Group Inc, Conestoga Capital Advisors, LLC, and Royce & Associates Lp. VC/PE firms and individual insiders also hold significant stakes, with Telegraph Hill Partners being a top shareholder, owning 70.5% of the company's shares.
